Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2012
06/14/2012WO2012079092A2 Testosterone undecanoate compositions
06/14/2012WO2012079047A2 Targeting kidney mesangium with nanoparticles of defined diameter
06/14/2012WO2012079043A2 Targeting kidney mesangium with nanoparticles of defined diameter
06/14/2012WO2012079035A1 Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
06/14/2012WO2012079024A2 Implantable devices coated with insulin-mimetic agent composites and methods thereof
06/14/2012WO2012078999A1 Compositions for treating dermatitis and ichthyosis, and methods for treating dermatitis and ichthyosis
06/14/2012WO2012078831A2 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
06/14/2012WO2012078815A1 Sustained release implants containing a biodegradable polymer, cyclodextrin and poorly water soluble active compounds
06/14/2012WO2012078761A2 Dimeric molecular complexes with free cysteine residues and conjugates thereof
06/14/2012WO2012078647A2 Chemical composition to detect and treat amyloid in a patient's brain and retina
06/14/2012WO2012078605A1 Topical combination formulations of macrocyclic lactones with synthetic pyrethroids
06/14/2012WO2012077950A2 Hyaluronic acid-protein conjugate and method for preparing same
06/14/2012WO2012077696A1 Stabilizer of acetaminophen
06/14/2012WO2012077651A1 Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
06/14/2012WO2012077131A1 A stable ready-to-use cetrorelix injection
06/14/2012WO2012076988A1 A complex of garcinol, cyclodextrin and method thereof
06/14/2012WO2012076941A1 Pyrrolo[2,1-c][1,4]benzodiazepine linked imidazo[1,5-a]pyridine conjugates as potential antitumour agents and process for the preparation thereof
06/14/2012WO2012076668A1 Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
06/14/2012WO2012075602A1 Ultrasonic microbubble target-locating controlled releasing drug/gene device and target transfer method
06/14/2012WO2012075581A1 Antibodies selective for cells presenting erbb2 at high density
06/14/2012WO2012075533A1 Multifunctional nanoparticles
06/14/2012WO2012056111A3 Drug delivery compositions
06/14/2012WO2012052478A3 Topical gel composition
06/14/2012WO2012050896A3 Protease selective supramolecular assemblies
06/14/2012WO2012035310A3 Therapeutic conjugates of a dextrin polymer and an antimicrobial peptide
06/14/2012WO2012033911A3 Polyionic papilloma virus-like particle (vlp) vaccines
06/14/2012WO2012018240A9 Preparation of extremely small and uniform sized, iron oxide-based paramagnetic or pseudo-paramagnetic nanoparticles and mri t1 contrast agents using the same
06/14/2012WO2011134979A3 Stable aqueous mia/cd-rap formulations
06/14/2012WO2011063990A8 Spider silk particles for controlled and sustained delivery of compounds
06/14/2012US20120149892 Nucleic Acid Molecules Encoding Antibodies That Bind Cell-Associated CA 125/O772P
06/14/2012US20120149877 Tumor-specific recognition molecules
06/14/2012US20120149784 Tabletting of erythritol and isomalt
06/14/2012US20120149783 Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
06/14/2012US20120149782 Carotenoid compositions containing modified gum acacia
06/14/2012US20120149781 Stem cell differentiation using novel light-responsive hydrogels
06/14/2012US20120149719 Bitter taste masking dosage form
06/14/2012US20120149630 End-modified poly(beta-amino esters) and uses thereof
06/14/2012US20120149578 Manipulation of Cloud Point for Two-Phase, Aqueous Polymeric Systems
06/14/2012US20120149085 Fusion proteins containing recombinant cytotoxic rnases
06/14/2012US20120149083 PEG-Urate Oxidase Conjugates and Use Thereof
06/14/2012US20120148687 Cranberry seed oil, cranberry seed flour and a method for making
06/14/2012US20120148672 Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
06/14/2012US20120148671 Gastric retained gabapentin dosage form
06/14/2012US20120148660 Conjugates of synthetic tlr agonists and uses therefor
06/14/2012US20120148610 Monomethylvaline compounds capable of conjugation to ligands
06/14/2012US20120148608 Monomethylvaline compounds capable of conjugation to ligands
06/14/2012US20120148596 Molecular conjugates comprising human monoclonal antibodies to dendritic cells
06/14/2012US20120148587 Polypeptide formulation
06/14/2012US20120148569 Picrorhiza kurroa extract for prevention, elimination and treatment of infection diseases
06/14/2012US20120148555 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
06/14/2012US20120148548 Joint Repair Using Mesenchymal Stem Cells
06/14/2012US20120148521 Methods and Compositions for Controlled Release of Drugs
06/14/2012US20120148514 N-alkyl lactam ethers, and compositions and uses thereof
06/14/2012US20120148505 Reduction In Bacterial Colonization By Administering Bacteriophage Compositions
06/14/2012US20120145590 Solvent Composition For Conversion Of Makeup Cosmetic
06/14/2012CA2821109A1 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
06/14/2012CA2821075A1 Hyaluronic acid-protein conjugate and method for preparing same
06/14/2012CA2820984A1 A complex of garcinol, cyclodextrin and method thereof
06/14/2012CA2820837A1 Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
06/14/2012CA2820671A1 Tnf-.alpha. binding proteins
06/14/2012CA2820630A1 Dimeric molecular complexes with free cysteine residues and conjugates thereof
06/14/2012CA2819554A1 Dosage and administration of bispecific scfv conjugates
06/14/2012CA2819548A1 Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
06/14/2012CA2819366A1 Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
06/14/2012CA2819038A1 Humanized antibodies to liv-1 and use of same to treat cancer
06/14/2012CA2818635A1 Antibodies selective for cells presenting erbb2 at high density
06/14/2012CA2817941A1 A stable ready-to-use cetrorelix injection
06/13/2012EP2463378A1 Alpha isomaltosylglucosaccharide synthase, process for producing the same and use thereof
06/13/2012EP2463308A1 Polymer Hydrogels and Medical Use Thereof
06/13/2012EP2462950A1 Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
06/13/2012EP2462940A1 Stabilized bacteriophage formulations
06/13/2012EP2462939A2 Bioabsorbable adhesive compounds and compositions
06/13/2012EP2462923A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
06/13/2012EP2462921A1 Liquid pharmaceutical compositions for the treatment of a posterior eye disease
06/13/2012EP2462896A1 Method for the preparation of controlled release formulations
06/13/2012EP2461840A1 Ion substituted calcium phosphate particles
06/13/2012EP2461832A2 Targeting of bone marrow neovasculature
06/13/2012EP2461831A1 Growth hormones with prolonged in-vivo efficacy
06/13/2012EP2461830A1 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
06/13/2012EP2461803A2 Fast-acting naproxen composition with reduced gastrointestinal effects
06/13/2012EP2461800A2 Controlled release formulations of lipocalin muteins
06/13/2012EP2461797A1 Process for preparation of over-the-counter gelatin or pectin-based drug delivery
06/13/2012EP2461679A1 Vaccine stabilizer
06/13/2012EP2461677A1 Concentrated polypeptide formulations with reduced viscosity
06/13/2012EP2243490B1 Insulin nasal powder inhalation
06/13/2012EP1842558B1 Composition for inhibiting expression of target gene
06/13/2012EP1740213B9 Liquid growth hormone formulation
06/13/2012EP1734927B1 Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
06/13/2012EP1675573B2 Controlled release sterile injectable aripiprazole formulation and method
06/13/2012EP1613273B1 Recombinant il-9 antibodies and uses thereof
06/13/2012EP1585542B1 Immunogenic compositions containing phospholipid
06/13/2012EP1516058B1 Recombinant measles viruses expressing epitopes of antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
06/13/2012EP1495053B1 Angiopoietin-2 and angiopoietin-1 specific binding agents
06/13/2012EP1490110B1 Anti-alpha v beta 6 antibodies
06/13/2012EP1414471B1 Therapeutic agents comprising pro-apoptotic proteins
06/13/2012EP1297017B1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
06/13/2012EP1296705B1 Amyloid Beta oligomers for use in treatment, alleviation or prevention of Alzheimer's Disease
06/13/2012EP1235594B1 Inhibition of secretion from non-neuronal cells
06/13/2012EP1104296B1 Bioimplant formulation
06/13/2012CN1743337B Taxol derivative and its pharmaceutical composition
1 ... 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 ... 1712